英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
colligere查看　colligere　在百度字典中的解释百度英翻中〔查看〕
colligere查看　colligere　在Google字典中的解释Google英翻中〔查看〕
colligere查看　colligere　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Amneal Receives U. S. FDA Approval for Brekiya® - GlobeNewswire
    DHE can be used at any point during a migraine attack, and may protect patients from headache recurrence 1, 3,4 Approximately 39 million Americans are living with migraine 7, and up to one
  • FDA Approves Brekiya, First and Only DHE Autoinjector, for . . .
    Unlike migraines, cluster headaches occur as frequent attacks (referred to as “clusters”), which result in intense pain in or around the eye or 1 side of the head These attacks can last for weeks to months 1-3 Headache is the fourth most common reason for ER visits, accounting for approximately 3% of ER visits in the United States
  • Amneal Pharmaceuticals, Inc. - Amneal Receives U. S. FDA . . .
    Brekiya ® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N J , May 15, 2025 (GLOBE NEWSWIRE) - Amneal Pharmaceuticals, Inc (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U S
  • FDA Approves Brekiya (dihydroergotamine mesylate) Injection . . .
    BRIDGEWATER, N J , May 15, 2025 -- Amneal Pharmaceuticals, Inc (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U S Food and Drug Administration (FDA) has approved Brekiya (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or
  • New Treatments for Migraines: What Actually Works in 2025?
    After two months of preventive use, patients experienced a reduction of 4 migraine days per month, with over 50% reporting at least a 50% reduction in moderate to severe headache days [23] Recently, Nerivio became the first non-pharmacological migraine treatment to receive commercial insurance coverage in the United States [24]





中文字典-英文字典  2005-2009